We showed previously that diploid human fibroblasts that express a transfected HRAS oncogene from the human bladder carcinoma cell line T24 exhibit several characteristics of transformed cells but do not acquire an infinite life-span and are not tumorigenic. To extend these studies ofthe T24 HRAS in human cells, we have utilized an infinite life-span, but otherwise phenotypically normal, human fibroblast cell strain, MSU-1
strain, MSU-1.1, developed in this laboratory after transfection of diploid fibroblasts with a viral v-myc oncogene. Transfection of MSU-1.1 cells with the T24 HRAS flanked by two transcriptional enhancer elements (pHO6T1) yielded foci of morphologically transformed cells. No such transformation occurred if the plasmid containing T24 HRAS had only one enhancer or none at all or if the normal human HRAS gene was transfected in the pHO6 vector (pHO6N1). Cell strains derived from such foci expressed high levels of T24 HRAS product p21, formed colonies in soft agar at high frequency, proliferated rapidly in serum-free medium that does not support growth of the parental cell line, and formed progressively growing, invasive fibrosarcomas. These foci-derived T24 HRAStransformed cell strains, as well as cells from the tumors derived from them, had the same near-diploid karyotype as that of the parental MSU-1.1 cells. Transfection of pHO6T1 into two other inflnite life-span human fibroblast cell lines, cells that had not been transfected with v-myc, also resulted in malignant transformation, suggesting that the infinite life-span phenotype of MSU-1.1 cells, and not necessarily expression of the v-myc oncogene, was the factor that complemented T24 HRAS expression to cause malignant transformation.
Oncogenes of the ras family have been detected in numerous and diverse human malignancies (1) . A growing body of evidence from both in vivo and in vitro studies suggests that the p21 products of ras oncogenes are involved in the genesis of such malignancies. For example, transgenic mice harboring the HRAS oncogene of the human bladder carcinoma cell line T24 (2) or the v-Ha-ras oncogene of Harvey murine sarcoma virus (3), linked to a promoter specific for expression in mammary tissue, developed mammary tumors. However, they did so only after a long latency, and the tumors were clonal in origin, suggesting that additional changes at the cellular level were required to cause tumor formation. Clues to the nature of the steps or events that may complement mutational activation ofras genes in tumorigenesis have come primarily from in vitro experiments utilizing rodent fibroblasts in culture (for a review, see ref. 1). For example, when primary or early-passage rodent fibroblasts with a finite life-span in culture were transfected with an HRAS oncogene, no transformation was seen, but when cells that had acquired an infinite life-span were used, fully transformed cells were obtained (4) . Similarly, when primary or earlypassage rodent cells were transfected with an HRAS oncogene and any one of a number of genes considered to be involved in causing cellular immortalization, malignant transformation resulted (5-7). Not surprisingly, transfection of HRAS oncogenes into infinite life-span rodent fibroblast cell lines resulted in malignant transformation (5, 8) in the majority of the studies (9) .
To test models proposed for ras transformation generated from experiments with rodent fibroblasts for their relevance to human cell transformation, we and our colleagues (10) (11) (12) and several other groups (13-21) have used human fibroblasts as target cells for transfection of HRAS or NRAS oncogenes or for infection with the Harvey or Kirsten murine sarcoma viruses. Two groups (14, 15, 17) reported that early-passage diploid human fibroblasts are resistant to transformation by transfected HRAS oncogenes. However, Hurlin et al. (10) showed that if such cells are transfected with the pHO6T1 plasmid, which contains the human T24 HRAS oncogene flanked by Moloney murine sarcoma virus long terminal repeat and simian virus 40 (SV40) transcriptional enhancer sequences in order to increase expression of this gene, they become morphologically transformed, develop distinct foci, and form colonies in soft agar. In a similar study, Tubo and Rheinwald (20) showed that diploid human fibroblasts transfected with the T24 HRAS oncogene in a plasmid that contains a SV40 transcriptional enhancer sequence become morphologically transformed and exhibit reduced growthfactor requirements. As discussed by Hurlin et al. (10) , the negative results referred to above (14, 15 17 ) most probably reflect lack of expression of the transfected HRAS oncogene or expression at a level too low to cause measurable effects. In the positive studies (10, 20) , where expression of the transfected T24 HRAS oncogene was higher than that of the normal HRAS gene, the transformants exhibited several characteristics of tumor-derived cells but did not acquire an infinite life-span or tumorigenicity.
The majority of the studies of the transforming ability of oncogenes carried out in rodent cells in culture have used fibroblasts that have acquired an infinite life-span in culture but are otherwise apparently normal. Until now, no comparable human cell lines have been available for use in testing the applicability of the results of such studies to human fibroblasts. The few infinite life-span, nontumorigenic human fibroblast cell lines that exist have been generated by using SV40 (22) or repeated exposure to carcinogen (23, 24) METHODS AND MATERIALS Cells and Culture Conditions. Cell line LG1, from which the MSU-1.1 cell strain arose, was initiated from foreskin material of a clinically normal newborn male as described (25) . The MSU-1.1 cell line, described above, is resistant to G418 (GIBCO) because the plasmid used to transfect the LG1 cells carried the aminoglycoside phosphotransferase gene. The infinite life-span human fibroblast cell lines KMST-6 and SUSM-1, generated after repeated carcinogen treatment (23, 24) , were obtained from M. Namba. The SV40-transformed infinite-life-span cell line GM0637B was purchased from the National Institute of General Medical Sciences (Human Genetic Mutant Cell Repository, Camden, NJ). The human bladder carcinoma cell line T24 was purchased from the American Type Culture Collection, and the chicken hepatoma, MC29 virus-producer cell line LSCC-DU72, was provided by K. Nazerian. The cells were routinely cultured in Eagle's minimal essential medium as described (10) . For studies of growth factor independence, McM medium [ref.
26; a modification of MCDB110 medium (27) ], formulated for use with serum-replacements, was used.
Plasmids and DNA Transfection. Plasmid pHO6T1 containing the T24 HRAS oncogene, pHO6N1 containing the normal human HRAS gene, and pHO6, which has no additional sequences (28), were provided by N. Wilkie. Plasmid pT24 was purchased from the American Type Culture Collection, and pSV2-T24 was constructed in this laboratory by inserting the T24 HRAS oncogene into the BamHI site of pSV2-neo (29) . Target cells (2 x 105) were transfected with DNA at 1.3 ,ug per ml by using the Polybrene/dimethyl sulfoxide method (30) as described (10) .
Assay for Growth Factor Independence. Cells (5 x 104) were plated in McM medium supplemented with 1% fetal bovine serum. After 24 hr, the number of cells was determined, and the medium was exchanged for McM medium containing 0.1 mM calcium and the serum replacements of Ryan et al. (26) but lacking epidermal growth factor. The medium was renewed 3 days later, and the number of cells was determined after another 3 days.
Assay for Anchorage Independence. Cells were assayed for the ability to form colonies in soft agar as described (10) with the following modifications. Cells (5000 per dish) were plated in top agar consisting of McM medium supplemented with 2% fetal bovine serum and 0.33% SeaPlaque agar (FMC, Rockland, ME). McM medium containing 2% fetal bovine serum was provided to cultures weekly. Colonies with diameters larger than 80 ,um were counted and sized electronically after 3 wk.
Tumorigenicity Assays. Exponentially growing cells (1 x 107) were injected subcutaneously into 4-to 8-wk-old BALB/c athymic mice that had been irradiated with 300 rads (1 rad = 0.01 Gy) from a 'Co source 24 hr previously. DNA Analysis. DNA was isolated as described (31) and analyzed for transfected sequences by the method of Southern (32) .
were labeled with [35S]methionine (New England Nuclear) at 250 uCi (1 uCi = 37 kBq) per ml for 18 hr in McM medium lacking methionine but supplemented with 1% fetal bovine serum. Cell lysis, immunoprecipitation with the ras (any species) p21-specific antibody Y13-259 (33), NaDodSO4/ PAGE, and fluorography were performed as described (10) . For analysis of v-myc-encoded p110, cells were labeled as above, but for only 1.5 hr. Cells were washed in ice-cold phosphate-buffered saline, lysed in lysis buffer (10 mM Tris HCl, pH 8.2/150 mM NaCl/1% sodium deoxycholate/ 1% Triton X-100/0.1% NaDodSO4/5 mM EDTA/2 mM phenylmethanosulfonyl fluoride), and clarified by centrifugation at 10,000 X g for 20 min. Supernatants containing 7 (34) in NaDodSO4/10% polyacrylamide gels, and the gels were fixed, treated with enhancer, dried, and exposed to x-ray film as described.
Karyotype Analysis. For each cell line, at least 25 G-banded karyotypes (35) were examined for chromosomal rearrangements, and 100 conventionally stained metaphases were counted to determine the modal chromosome number.
RESULTS
Transformation to Focus Formation by the Human T24 HRAS Oncogene. After transfection, the MSU-1.1 cells were cultured for 3 wk in Eagle's medium containing 10o fetal bovine serum and screened for colonies ofcells that overgrew the monolayer (foci). Cells that had been transfected with pHO6T1 formed distinct foci of morphologically altered cells at a frequency of 10 per 106 cells transfected. No foci or indications of transformation were observed after transfection with control plasmids either containing the normal human HRAS gene (pHO6N1) or lacking a ras gene (pHO6). Transfection of 5 x 106 MSU-1.1 cells with plasmids containing the T24 HRAS oncogene but no enhancer sequences (pT24) or with only one SV40 transcriptional enhancer (pSV2-T24) did not induce focus formation. Six populations of morphologically transformed cells (designated MSU-1.1-T24 strains 1-6) were isolated from foci in separate dishes and were expanded for subsequent characterization. Fig. 1 shows an example of the morphology of such cells, along with that of the parental MSU-1.1 cell strain and LG1 cells, from which it arose. The MSU-1.1-T24 cells were smaller, rounder, and more refractile than the other two cell types. These six cell strains have maintained their transformed Analysis for T24 HRAS-Encoded p21 and v-myc-Encoded p110. Cells to be analyzed for all human RAS-encoded p21 Growth of MSU-1.1-T24 Fibroblasts in Serum-Free Medium. Schilz et al. (36) found that human fibrosarcomaderived cell lines, but not normal human fibroblasts, were capable of proliferating in McM medium containing 0.1 mM calcium instead of the usual 1 mM, supplemented with the serum replacements of Ryan et al. (26) , but lacking epidermal growth factor. To determine their growth factor independence, MSU-1.1-T24 cell strains, the parental MSU-1.1 cells, and LG1 cells were compared for ability to proliferate in this medium. The MSU-1.1-T24 cell strains proliferated 6-to 7-fold more than the MSU-1.1 cells did ( Table 1) . As expected, LG1 cells could not proliferate. The number of cells attained by the MSU-1.1-T24 cell strains was similar to that attained in medium containing 10% fetal bovine serum.
Anchorage Independence of MSU-1.1-T24 Cell Strains. When tested for ability to form colonies in agar, LG1 cells and MSU-1.1 cells did so with an efficiency of <0.007% (i.e., no colonies were detected out of a total of 15,000 cells plated), whereas MSU-1.1-T24 cell strains formed colonies with efficiencies from 3.5% to 23% (Table 1 ). There was variation in the size range of colonies detected. For example, although MSU-1.1-T24 strain 6 exhibited an agar cloning efficiency of only 3.5%, it gave rise to the highest proportion of very large colonies (i.e., having diameters of >300 Am).
Tumorigenicity ofMSU-1.1-T24 Cell Strains. Four ofthe six MSU-1.1-T24 cell strains injected into athymic mice formed progressively growing tumors that reached 1 cm in diameter within 30-36 days (Table 1 ). These were diagnosed as poorly differentiated, invasive fibrosarcomas with a high mitotic index and a moderate degree of anaplasia. A low proportion of giant multinucleated cells were observed in several tumors. A histological section of a representative tumor is shown in Fig. 2 . Several criteria indicated that the tumors were formed by the injected MSU-1.1-T24 cell strains (see below).
Presence of T24 HRAS Oncogenes. After digestion of genomic DNA with Xba I and HindIlI, fragments of 4.5 and 2.5 kb that hybridize with the Sac I 2.9-kb fragment ofthe T24 HRAS oncogene are diagnostic for plasmid pHO6T1 sequences, which include the T24 HRAS oncogene and flanking 5' and 3' transcriptional enhancer sequences (28) . Genomic (Fig. 4) . To determine the relative levels of RAS p21 expression, the radiolabeled p21 bands were cut out of duplicate gels and quantitated by scintillation counting. The level of total RAS p21 expression in the MSU-1.1-T24 cell strains was 3-5 times that expressed in parental MSU-1.1 cells or in LG1 cells and was only slightly increased over that observed in bladder carcinoma-derived cells. Radioimmunoprecipitation analysis of RAS p21 was also carried out on fibroblasts taken from the malignant tumors derived from two of the MSU-1.1-T24 cell strains (37) . The RAS-encoded p21 levels in these cells were comparable to those in their respective focus-derived cell strains, indicating that in vivo selection of cells expressing higher ( virus indicated the presence of the v-myc gene in the six MSU-1.1-T24 cell strains (37) . The v-myc-hybridizing DNA fragments were of identical size and intensity as those detected in the parental MSU-1.1 cells, indicating that no rearrangements or amplification of this oncogene had occurred subsequent to introduction of pH06T1.
Radioimmunoprecipitation analysis indicated that in the MSU-1.1-T24 cell strains, v-myc-encoded p110 was expressed at levels comparable to that found in the parental MSU-1.1 cells (Fig. 5) . As expected, no v-myc p110 was detected in the LG1 cells. A chicken hepatoma cell line expressing a v-myc p110 was used as a positive control in this analysis.
Karyotype Analysis of MSU-1.1-T24 Cell Strains. G-banded and conventionally stained chromosomes from MSU-1.1-T24 cell strains and cells from malignant tumors derived from them were analyzed and compared with that obtained with the parental MSU-1.1 cells. The G-banded karyotype of each set of cells was identical. Their modal chromosome number was 45, including two marker chromosomes.
Transformation Studies with Other Infinite Life-Span Human Fibroblast Cell Lines. Three other life-span cell lines that had not been transfected with the v-myc oncogene-i.e., SUSM-1 (23), , and GM0637B-also were transfected with pH06T1 and pH06N1. The transfectants were selected for G418 resistance rather than for focus formation because, unlike the parental MSU-1.1 cell line, these target cells already exhibit a transformed morphology and aberrant growth behavior. The G418-resistant colonies obtained with each cell line were pooled, and their progeny were tested for tumorigenicity. Four of five mice injected with pHO6T1-transfected KMST-6 cells and three of six injected with pHO6T1-transfected GM0637B cells developed progressively growing malignant fibrosarcomas. No tumors were formed in five mice injected with pHO6T1-transfected SUSM-1 cells generated in two separate experiments or with any of the pH06N1-transfected G418-resistant controls. Immunoprecipitation studies with these pooled populations (37) indicated that the KMST-6 and GM0637B-T24 transfec- 
DISCUSSION
From the results of this study with the infinite life-span MSU-1.1 cells and those of our earlier study (10) cells, we conclude that "immortalized" nontumorigenic human fibroblasts can be transformed into malignant cells by transfection of the T24 HRAS oncogene and its subsequent expression. The tumors formed by the MSU-1.1-T24 cell strains grew progressively and were diagnosed as invasive fibrosarcomas. The two cell strains that did not give rise to tumors, even though they expressed the T24 HRAS gene and exhibited the other transformed characteristics, were retested in a separate experiment and again proved to be nontumorigenic. The reasons for their lack of tumor formation are not yet understood.
Since the karyotype of the malignant cells derived from the tumors matched the karyotype of the MSU-1.1-T24 cells injected and both karyotypes were identical to that observed in the nontumorigenic parental MSU-1.1 cell line from the earliest passage tested postcrisis, we conclude that the tumorigenic phenotype in these T24 HRAS-transformed cell strains did not arise as the result of chromosome changes.
Although the MSU- (19, 21) , who utilized KMST-6 cells. In their studies, introduction of ras oncogenes by either virus infection (18, 19) or by transfection (21) resulted in cells able to form tumors in athymic mice, although, in contrast to our results with the SV40-immortalized GM0637B cells, the tumors produced with the Va2 cells did not grow progressively (18) -an important criterion for malignant transformation, along with the ability to invade.
The significance of studies of the in vitro transformation of human fibroblasts by activated RAS genes ultimately depends on whether activated RAS genes play a causal role in the malignant transformation of human fibroblasts in vivo. Of particular relevance, therefore, are the findings that activated (mutated) NRAS genes have been found in human fibrosarcoma-derived cell lines HT1080 (38) and SHAC (39) . Whether the mutation occurred in the cells that gave rise to the original tumor or arose during passage of the cells in culture cannot be ascertained from such studies. However, the observation that the tumorigenicity of the HT1080 cell line is dependent upon the cells' containing more copies of the mutant NRAS gene than of the normal gene (40) suggests that the activated RAS gene was required for tumorigenicity in vivo. Although it has often been reported that human fibroblasts are refractory to transformation, in fact, they readily express various transformed phenotypes (cf. ref. 41 ). The present study and those discussed above indicate that activated HRAS and NRAS genes can malignantly transform infinite life-span human fibroblasts. Finite life-span human fibroblasts transfected with activated RAS oncogenes express identical characteristics but do form malignant tumors (10) (11) (12) 20) . The simplest explanation of why an infinite life-span is required for malignant transformation is that without it, the transformed cell has too few potential doublings left to form a tumor (42) . Since infinite life-span human fibroblast cell lines have never been reported to arise spontaneously, and only very rarely arise after SV40 or carcinogen treatment, the apparent "refractoriness" of these cells to malignant transformation appears to result from the low frequency at which infinite life-span cell strains arise.
